News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals to Participate in the Stifel 2020 Virtual Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Update
Year-to-Date Net Revenues of $58.5 Million Increased 29% over 2019 Third Quarter Net Revenues of $20.1 Million or $77 Per Bottle U.S. Dry Eye Trial Initiated and Japanese Glaucoma Trial Set to Commence Conference Call and Webcast Today, November 5 th , at 5:00 p.m. ET DURHAM, N.C.
View HTML
Toggle Summary Aerie Pharmaceuticals Initiates Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye Disease
-First Patient Dosed in 90-Day Efficacy Trial Named COMET-1- DURHAM, N.C. --(BUSINESS WIRE)--Oct. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries
OSAKA, Japan & DURHAM, N.C. --(BUSINESS WIRE)--Oct. 28, 2020-- Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an exclusive development and commercialization agreement for Rhopressa ® and Rocklatan
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 27, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-15512 (TRPM8 Agonist) Eye Drop for Dry Eye Disease
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 29, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Successful Interim 90-Day Topline Data From Its Six-Month Mercury 3 Clinical Trial in Europe
- Roclanda ® Achieves Non-Inferiority to Ganfort ® - - Mercury 3 Performance Exceeds Prior Phase 3 Trials - DURHAM, N.C. --(BUSINESS WIRE)--Sep. 24, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 15, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases
View HTML
Toggle Summary Aerie Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 8, 2020-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
Year-to-Date Net Revenues of $38.4 Million Increased 44% over 2019 Positive Phase 2 Topline Results for AR-1105 Implant Indicate up to Six-Month Sustained Release AR-15512 Trial for Dry Eye, COMET-1, Set to Initiate this Year Conference Call and Webcast Today, August 6 th , at 5:00 p.m.
View HTML
TOP